Robert Lorne Hopfner, Director at Vaxcyte, Inc. (PCVX), sold 266,031 shares at $29.24 ($7.5M) on 2021-01-06, disclosed to the SEC on 2021-01-08.
Open-market sale of $7.5M PCVX by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $29.24 | 34,913 | $1.0M | 13.5% |
| 2 | $29.24 | 34,913 | $1.0M | 13.5% |
| 3 | $29.99 | 22,507 | $675K | 9.0% |
| 4 | $29.99 | 22,507 | $675K | 9.0% |
| 5 | $27.75 | 24,524 | $681K | 9.0% |
| 6 | $28.80 | 22,587 |
| $651K |
| 8.6% |
| 7 | $28.80 | 22,587 | $651K | 8.6% |
| 8 | $29.51 | 469 | $14K | 0.2% |
| 9 | $26.43 | 31,468 | $832K | 11.0% |
| 10 | $26.43 | 31,468 | $832K | 11.0% |
| 11 | $27.08 | 8,944 | $242K | 3.2% |
| 12 | $27.08 | 8,944 | $242K | 3.2% |
| 13 | $28.23 | 200 | $6K | 0.1% |
| Total | $28.34 avg | 266,031 | $7.5M | 100% |
| Filing → |
| INZY | BUY | 2023-05-15 | $5.7M | — | Filing → |
| INZY | BUY | 2023-03-30 | $3.1M | — | Filing → |
| INZY | BUY | 2023-03-29 | $1.7M | — | Filing → |